c/tirzepatide wiki

What this community is for

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

c/tirzepatide was created on 9 Aug 2023 and currently has 187,300 members and 130 captured submissions. It sits in the busiest tier of the site, which mostly affects how fast a question gets answered rather than how well.

Rules, and why each exists

Community rules come first, then the six site-wide rules that apply everywhere on GLP Research Hub. Community rules are enforced by the moderators listed at the bottom of this page; site rules are enforced by everyone.

1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.

And the site rules, which are short on purpose:

1. Independent community. Nobody here sells anything, and anyone who tries is banned.
2. Not medical advice. Describe what you did; never prescribe to a stranger.
3. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
4. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
5. No contact handles, wallet addresses or tracking numbers — they identify people.
6. Be recognisably decent. Disagree hard, insult nobody.

Terms you will see

Vocabulary that turns up constantly in c/tirzepatide. Each links to the topic page, which collects every submission that touches it.

• tirzepatide — dual GIP/GLP-1 receptor agonist; the SURMOUNT and SURPASS programme drug.
• Mounjaro — discussed frequently in this community — see the topic page for every submission that touches it.
• Zepbound — discussed frequently in this community — see the topic page for every submission that touches it.
• GIP — discussed frequently in this community — see the topic page for every submission that touches it.
• SURMOUNT — discussed frequently in this community — see the topic page for every submission that touches it.
• SURPASS — discussed frequently in this community — see the topic page for every submission that touches it.
• 15mg — discussed frequently in this community — see the topic page for every submission that touches it.
• dual agonist — discussed frequently in this community — see the topic page for every submission that touches it.

Start here

The twelve highest-scoring submissions in this community. Not necessarily the most correct — the most agreed-with, which is a different thing, and worth remembering when you read them.

1. what changed for me between month 6 and month 14 — 12k points, 63 comments, 1 year ago
2. [Meta] the GIP rule is doing its job and people should stop complaining — 11k points, 44 comments, 1 year ago
3. help me understand 15mg, I have read the wiki twice — 11k points, 44 comments, 1 year ago
4. [Discussion] we are measuring GIP at the wrong time and calling it noise — 10k points, 56 comments, 2 years ago
5. [Discussion] can we stop arguing about dual agonist until somebody posts a number — 8.8k points, 40 comments, 2 years ago
6. [Vendor] QST vs WWB on the same compound, same month — both cleared 99.0% — 8.5k points, 61 comments, 2 years ago
7. [Meta] proposal — a flair for SURMOUNT posts — 7.7k points, 26 comments, 1 year ago
8. [Question] 15mg — what am I missing here — 7.4k points, 37 comments, 2 years ago
9. [Vendor] QST vs QYB on the same compound, same month — both cleared 99.0% — 7.4k points, 62 comments, 2 years ago
10. week 16 check-in — 5kg down, reflux manageable, one thing confusing me — 7k points, 53 comments, 2 years ago
11. my fasting insulin moved and I cannot work out whether Zepbound is why — 6.7k points, 38 comments, 2 years ago
12. tirzepatide — 22 things I got wrong before I got it right — 6.6k points, 22 comments, 5 months ago

Asked constantly

• 2.5 → 5 → 7.5 in six weeks was a mistake, here is what happened
• my resting HR went from 58 to 66 on titration and settled back
• [Question] does the vial concentration change how much dead space costs me
• what would you tell week-1 you about GIP
• nobody warned me about muscle cramps and I would have liked the warning
• small win: Mounjaro stopped being a problem at week 45
• [PSA] SURPASS is not what most of this community thinks it is
• [Question] dual agonist — what am I missing here
• [Question] Mounjaro — what am I missing here
• [Question] is 99.3% actually fine or am I being sold a rounding error

If your question is on that list, read the answers there first. If it is not, ask it — that is what the community is for, and "this has been asked" is only a helpful reply when it comes with a link.

Who runs this

Moderation here is done by volunteers who also post as normal members. They are not clinicians, not vendors, and not paid.

• u/titration_marshal — c/semaglutide mod. No, you should not jump to 2.4 in week three.
• u/incretin_ivy — GIP/GLP-1 co-agonism is genuinely interesting pharmacology, separate from the weight story.
• u/quiet_moderator — I remove the obvious stuff so you never see it. Message the modmail, not me.
• u/dexa_twice_yearly — Two DEXA scans a year. Lean mass held at 92% while fat mass halved. Resistance training.